Roger Daher
Founder at CANACCORD GENUITY G VENTURES CORP.
Net worth: 301 126 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Danziger | M | 67 |
Aumento Capital V Corp.
 Aumento Capital V Corp. Financial ConglomeratesFinance Aumento Capital V Corp. is a capital pool company. It engages in the identification and evaluation of assets or businesses with a view to complete a qualifying transaction. The company was founded on July 16, 2014 and is headquartered in Toronto, Canada.
CannBioRex Pharmaceuticals Corp.
 CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada.
Aumento Capital VI Corp.
 Aumento Capital VI Corp. Financial ConglomeratesFinance Aumento Capital VI Corp. is a capital pool company, which engages in the identification and evaluation of assets or businesses with a view to completing a Qualifying Transaction ("QT"). It has no commenced commercial operations and has no assets other than cash. The company was founded on January 6, 2017 and is headquartered in Toronto, Canada.
Aumento Capital III Corp.
 Aumento Capital III Corp. Financial ConglomeratesFinance Aumento Capital III Corp. operates as a capital pool company, that seeks to acquire an operating business. The company's principal business is to identification and evaluation of assets and businesses with a view to complete a proposed qualifying transaction. Aumento Capital III was founded on May 5, 2011 and is headquartered in Toronto, Canada.
Aumento Capital X Corp.
 Aumento Capital X Corp. Financial ConglomeratesFinance Aumento Capital X Corp. engages in the provision of investment services. The company was founded on March 4, 2022, and is headquartered in Toronto, Canada. | 13 years |
| Sumesh Paul Pathak | M | 55 |
Aumento Capital VI Corp.
Aumento Capital VI Corp. Financial ConglomeratesFinance Aumento Capital VI Corp. is a capital pool company, which engages in the identification and evaluation of assets or businesses with a view to completing a Qualifying Transaction ("QT"). It has no commenced commercial operations and has no assets other than cash. The company was founded on January 6, 2017 and is headquartered in Toronto, Canada.
Aumento Capital III Corp.
Aumento Capital III Corp. Financial ConglomeratesFinance Aumento Capital III Corp. operates as a capital pool company, that seeks to acquire an operating business. The company's principal business is to identification and evaluation of assets and businesses with a view to complete a proposed qualifying transaction. Aumento Capital III was founded on May 5, 2011 and is headquartered in Toronto, Canada.
Aumento Capital X Corp.
Aumento Capital X Corp. Financial ConglomeratesFinance Aumento Capital X Corp. engages in the provision of investment services. The company was founded on March 4, 2022, and is headquartered in Toronto, Canada.
Aumento Capital V Corp.
Aumento Capital V Corp. Financial ConglomeratesFinance Aumento Capital V Corp. is a capital pool company. It engages in the identification and evaluation of assets or businesses with a view to complete a qualifying transaction. The company was founded on July 16, 2014 and is headquartered in Toronto, Canada. | 13 years |
| Henry Batievsky | M | - | 6 years | |
| Paul A. Kelly | M | 65 | 10 years | |
| Kevin Kirby | M | - | 3 years | |
| Jonathan Rothbard | M | 72 |
CannBioRex Pharmaceuticals Corp.
CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | - |
| Andrew Parks | M | 38 | 7 years | |
| Michael Shuh | M | 55 | 3 years | |
| Nick DeMare | M | 69 |
CannBioRex Pharmaceuticals Corp.
CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 years |
| Lawrence Pemble | M | 36 |
CannBioRex Pharmaceuticals Corp.
CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 years |
| William M. Smith | M | - | 3 years | |
| Robert Beasley | M | - | 4 years | |
| Raphael Mechoulam | M | - |
CannBioRex Pharmaceuticals Corp.
CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 years |
| Charanjit Bountra | M | 63 |
CannBioRex Pharmaceuticals Corp.
CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 years |
| Mike LeClair | M | - | 5 years | |
| Morris Prychidny | M | 77 | 10 years | |
| Christopher Paige | M | 71 |
University Health Network
 University Health Network Hospital/Nursing ManagementHealth Services University Health Network operates as a healthcare and medical research organization that provides patient care, education, and research services. Its programs include arthritis program, joint department of medical imaging, Krembil neuroscience center, laboratory medicine program, medical and community care, multi-organ transplant, Peter Munk cardiac center, Princess Margaret cancer, surgery and critical care program, and Toronto rehab. The company was founded in 1986 and is headquartered in Toronto, Canada.
University of Toronto
| 37 years |
| Todd Buchman | M | - | 5 years | |
| Michael Galloro | M | 49 | 6 years | |
| Marc Feldmann | M | 79 |
CannBioRex Pharmaceuticals Corp.
CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 years |
| Yu Hyeon Chung | M | - | 3 years | |
| John Mazarakis | M | 47 | 1 years | |
| Mark Eckenrode | M | - | - | |
| Natalia Velasco | F | - | 7 years | |
| Jeffrey Batliner | M | 58 | 1 years | |
| Samantha Hymes | F | - | - | |
| Lawrence Steinman | M | 76 |
CannBioRex Pharmaceuticals Corp.
CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 years |
| Harry Ruda | M | 65 |
University of Toronto
| 35 years |
| Richard Williams | M | 67 |
CannBioRex Pharmaceuticals Corp.
CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | 6 years |
| Sean Mansouri | M | - | - | |
| Jackie Allen | F | - | 3 years | |
| Matthew Davis | M | - | 3 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Neal A. Hochberg | M | - | 3 years | |
| Steven Haasz | M | 53 | - | |
| Emlyn David | M | 61 |
Chudleigh Ventures, Inc.
 Chudleigh Ventures, Inc. Financial ConglomeratesFinance Chudleigh Ventures, Inc. is a capital pool company. It intends to identification and evaluation of assets or business with a view to completing a qualifying transaction. The company was founded on May 9, 2008 and is headquartered in Toronto, ON. | 2 years |
| Muneeb Yusuf | M | 41 | 4 years | |
| Teichman von Matthew | M | - | 5 years | |
| Pankaj Modi | M | 69 |
Chudleigh Ventures, Inc.
Chudleigh Ventures, Inc. Financial ConglomeratesFinance Chudleigh Ventures, Inc. is a capital pool company. It intends to identification and evaluation of assets or business with a view to completing a qualifying transaction. The company was founded on May 9, 2008 and is headquartered in Toronto, ON. | 4 years |
| Stuart R. Nayman | M | - |
University of Toronto
| 7 years |
| Valdis Martinsons | M | - |
University of Toronto
| 7 years |
| Wai Cheong Ng | M | 55 |
University of Toronto
| 7 years |
| James M. Brown | M | - | - | |
| Mazen Hassounah | M | - |
University of Toronto
| 5 years |
| Brian Miron | M | - |
University of Toronto
| 5 years |
| Andrew Woo | M | - |
University of Toronto
| 6 years |
| David Abrams | M | 57 | 3 years | |
| Fiona J. Kelly | F | - |
University of Toronto
| 3 years |
| Joseph Cargnelli | M | 54 |
University of Toronto
| 6 years |
| Jing Peng | M | 47 |
Aumento Capital VI Corp.
Aumento Capital VI Corp. Financial ConglomeratesFinance Aumento Capital VI Corp. is a capital pool company, which engages in the identification and evaluation of assets or businesses with a view to completing a Qualifying Transaction ("QT"). It has no commenced commercial operations and has no assets other than cash. The company was founded on January 6, 2017 and is headquartered in Toronto, Canada. | - |
| Davin Andrew Gibbins | M | - |
University of Toronto
| 5 years |
| Ira Kagan | M | 61 |
University of Toronto
| 7 years |
| Hamid Mumin | M | - |
University of Toronto
| 4 years |
| Mathew Walsh | M | - | - | |
| Jonathan Anschell | M | 56 |
University of Toronto
| 6 years |
| Matthew D. Willer | M | 47 | - | |
| Cindy Leung | F | - | 4 years | |
| Cheong Szeto | M | 54 |
University of Toronto
| 6 years |
| Michael Lovsin | M | - | 3 years | |
| Anna Marie Tham | F | 60 |
University of Toronto
| 6 years |
| Justin Guerin | M | - | 7 years | |
| Liora Boudin | F | - | 3 years | |
| Andrew Pyle | M | - |
University of Toronto
| 5 years |
| Blair Tamblyn | M | - | 4 years | |
| Chris Ouslis | M | - |
University of Toronto
| 6 years |
| James Haggarty | M | 59 | 5 years | |
| Gerald D. Mintz | M | 71 |
University of Toronto
| 3 years |
| Thomas Kierans | M | 81 | - | |
| Michael Boyd | M | 71 | 4 years | |
| Alicia Damley | F | - |
University of Toronto
| 7 years |
| Maria Pacella | F | - | 2 years | |
| James Stanley Walker | M | 60 | - | |
| Bill Maslechko | M | 63 |
University of Toronto
| 4 years |
| John McKimm | M | - | 5 years | |
| Jon A. Douglas | M | 61 |
University of Toronto
| 4 years |
| Alec Regis | M | 50 | 6 years | |
| Kwok Cheung Chan | M | 62 |
University of Toronto
| 6 years |
| Richard Romano | M | - |
University of Toronto
| 6 years |
| Flora Wood | F | - |
University of Toronto
| 5 years |
| John Docherty | M | 53 |
University of Toronto
| 6 years |
| Joseph Grech | M | - |
University of Toronto
| 4 years |
| Vincent Mifsud | M | - |
University of Toronto
| 4 years |
| Brian T. McGee | M | 63 |
University of Toronto
| 4 years |
| Vito Culmone | M | 59 |
University of Toronto
| 4 years |
| David William Briggs | M | - |
University of Toronto
| 4 years |
| Warren John Stoddart | M | - |
University of Toronto
| 4 years |
| Clifford Hale-Sanders | M | - |
University of Toronto
| 4 years |
| MacMurray D. Whale | M | - |
University of Toronto
| 4 years |
| Kathleen Skerrett | F | - |
University of Toronto
| 7 years |
| Elmer Kim | M | - |
University of Toronto
| 4 years |
| Philip Evershed | M | 63 |
University of Toronto
| 1 years |
| Kresimir Begic | M | - |
University of Toronto
| 4 years |
| Stephen Wallace Richards | M | - |
University of Toronto
| 4 years |
| Wendy Ford | F | - |
University of Toronto
| 4 years |
| Tom Kierans | M | - |
Chudleigh Ventures, Inc.
Chudleigh Ventures, Inc. Financial ConglomeratesFinance Chudleigh Ventures, Inc. is a capital pool company. It intends to identification and evaluation of assets or business with a view to completing a qualifying transaction. The company was founded on May 9, 2008 and is headquartered in Toronto, ON. | - |
| Mark Kociancic | M | 54 |
University of Toronto
| 4 years |
| Steven Mintz | M | 57 |
University of Toronto
| 4 years |
| Anna Marks | F | - |
University of Toronto
| 4 years |
| Wai Yee Yiu | F | 56 |
University of Toronto
| 4 years |
| Paul Mancuso | M | 59 |
University of Toronto
| 4 years |
| Kelly Battle | F | - |
University of Toronto
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 86 | 86.00% |
| United States | 14 | 14.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Roger Daher
- Personal Network